Previous human studies have shown systemic levels of TGFβ1 increase in type-1 and type-2 DM, obesity with insulin resistance, and diabetic nephropathy [11,21,34,35,36,37,38,39]. Here, TGFB1 is linked to diabetic kidney disease.